[Immunity related to cytomegalovirus after allogenic bone marrow transplantation: role of donor immunity to cytomegalovirus in the incidence of cytomegalovirus infection in recipients].
Cytomegalovirus infections are severe and frequent after BMT. This study included 34 bone marrow transplant recipients (23 aplastic anaemias and 11 leukaemias), their marrow donors and 125 related or non related normal controls. Assays were performed before transplantation and every 30 days between D 0 and D 90, and then every six months. They included detection of CMV induced lymphocyte proliferation in vitro, CMV antibody determinations by complement fixation and reverse haemagglutination, viraemia and/or viruria. Similarly, cellular immunity to mitogens and to other specific antigens was evaluated. During the period of study, 22 patients developed CMV infection. The diagnostic was confirmed by virus isolation from the 12th to the 96th day after the graft. Development of positive CMV proliferation test occurred from the 9th to the 84th day after virus isolation (30 to 120th day after the graft). In one case, the CMV infection was only proved by the lymphocyte proliferation to CMV in vitro and only 60 days later by viruria and 105 days later by detection of CMV antibodies. For the other 12 patients (7 aplasies and 5 leukaemias) and 10 of their bone marrow donors, no CMV infection was proved, before or after transplant, by any of the assays performed. By selecting a donor without previous CMV infection, we hope to reduce the incidence of CM infection in recipients.
D000741:Anemia, Aplastic / Q000628:therapy; D000914:Antibodies, Viral / Q000032:analysis; D016026:Bone Marrow Transplantation; D003168:Complement Fixation Tests; D003587:Cytomegalovirus / Q000276:immunology*; D003586:Cytomegalovirus Infections / Q000209:etiology / Q000276:immunology*; D006801:Humans; D007111:Immunity, Cellular; D007938:Leukemia / Q000628:therapy; D008213:Lymphocyte Activation; D014184:Transplantation, Homologous / Q000009:adverse effects*
D000914:Antibodies, Viral
Immunité vis-à-vis du cytomégalovirus après greffe de moelle osseuse allogénique: Rôle de l'immunité du donneur vis-à-vis du cytomégalovirus dans l'incidence de l'infection à cytomégalovirus chez les receveurs.